Loading stock data…
INBX
$128.79-0.42 (-0.33%)
After Hours$128.79+0.00 (+0.00%)· Last close May 1
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Inhibrx Biosciences, Inc. in the Healthcare sector is trading at $128.22. The stock is currently near its 52-week high of $155.29, remaining 108.4% above its 200-day moving average. Technical signals show overbought RSI of 83 and bullish MACD crossover, explaining why INBX maintains its current momentum and trend strength. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 83) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$128.79
Potential Upside
5%
Whystock Fair Value$135.23
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Buy
Mean target$300.00+132.9%
Range$300.00 – $300.00
Fundamentals
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1752.22%
Volume
Today's trading volume
326,120
Recent News
Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA Plans
Inhibrx Biosciences recently reported updated interim Phase 1/2 data showing that ozekibart (INBRX-109) plus FOLFIRI produced a 20% objective response rate, 5.5-month median progression-free survival and 87% disease control in heavily pretreated, unresectable metastatic colorectal cancer, with a manageable safety profile and no significant liver toxicity. The company is leveraging these data to pursue FDA discussions on registrational trials and potential accelerated pathways, while also...
Inhibrx Biosciences Highlights 20% ORR for Ozekibart Combo in Late-Line Colorectal Cancer
Inhibrx Biosciences (NASDAQ:INBX) shared a clinical update on ozekibart in advanced colorectal cancer, highlighting Phase I/II data evaluating ozekibart in combination with FOLFIRI in a heavily pretreated population that company executives said has historically seen minimal benefit from standard opt
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
Inhibrx Biosciences stock surges after phase I/II CRC data of ozekibart show strong response rates and durable benefit, alongside a new FDA filing for ozekibart in chondrosarcoma.
Top Midday Stories: GE Vernova Shares Gain on Strong Q1 Earnings, Guidance; Vertiv Lifts Guidance After Q1 EPS, Revenue Beats, Shares Fall
All three major US stock indexes were up in late-morning trading Wednesday following reports of Iran
Coinbase downgraded, Deere upgraded: Wall Street's top analyst calls
Coinbase downgraded, Deere upgraded: Wall Street's top analyst calls